Valneva SE reported its financial results for the first quarter ending March 31, 2025, with total revenues reaching €49.2 million, a significant increase from €32.8 million in the first quarter of 2024. Total product sales were €48.6 million, driven by double-digit growth in IXIARO®/JESPECT® and DUKORAL® sales.
IXIARO®/JESPECT® sales increased by 65.5% to €27.5 million, partly due to prior-year supply constraints, and DUKORAL® sales grew 9.4% to €12.3 million, supported by a supply to Mayotte. IXCHIQ® sales increased to €3.0 million, with most of the 40,000 doses supplied to La Réunion shipped in April 2025.
The company confirmed its 2025 financial guidance, anticipating product sales between €170 million and €180 million. However, the report noted recent changes in recommendations for IXCHIQ® use in the U.S. and France, and a temporary suspension by the EMA for individuals over 65 years old, following reports of serious adverse events in elderly individuals. Valneva is committed to monitoring these events and cooperating with health authorities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.